Literature DB >> 3680615

Interconversion between haloperidol and reduced haloperidol in humans.

K K Midha, E M Hawes, J W Hubbard, E D Korchinski, G McKay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3680615

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  15 in total

1.  Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.

Authors:  H K Roh; J Y Chung; D Y Oh; C S Park; J O Svensson; M L Dahl; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

2.  Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia.

Authors:  M W Kelly; P J Perry; W H Coryell; D D Miller; S V Arndt
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

Authors:  W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 4.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol.

Authors:  D W Eyles; H A Whiteford; T J Stedman; S M Pond
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Pharmacokinetics of a nootropic agent, BMY-21502, and its metabolites in beagle dogs.

Authors:  N Srinivas; S Kaul
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

7.  Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.

Authors:  M W Jann; Y W Lam; W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Biliary excretion of reduced haloperidol glucuronide.

Authors:  N D Eddington; D Young
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6.

Authors:  D Young; K K Midha; M J Fossler; E M Hawes; J W Hubbard; G McKay; E D Korchinski
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

Authors:  R F Tyndale; W Kalow; T Inaba
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.